Rep. Gilbert Ray Cisneros, Jr. Sells Shares of AtriCure, Inc. (NASDAQ:ATRC)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in AtriCure stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

AtriCure Price Performance

ATRC stock opened at $56.87 on Wednesday. The firm has a 50 day moving average of $51.69 and a 200-day moving average of $37.70. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $61.70. The firm has a market capitalization of $2.89 billion, a P/E ratio of 270.82 and a beta of 1.24.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same quarter in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Harbor Investment Advisory LLC bought a new stake in shares of AtriCure during the 2nd quarter worth $40,000. Allworth Financial LP purchased a new position in AtriCure in the second quarter worth $43,000. Integrated Wealth Concepts LLC bought a new position in AtriCure in the second quarter valued at $46,000. Fifth Third Bancorp bought a new position in AtriCure in the first quarter valued at $51,000. Finally, Global Retirement Partners LLC purchased a new stake in AtriCure during the second quarter valued at about $52,000. 99.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ATRC shares. Needham & Company LLC boosted their price target on shares of AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Freedom Capital downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. BTIG Research increased their price objective on AtriCure from $55.00 to $63.00 and gave the stock a “buy” rating in a research report on Monday. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Finally, Stifel Nicolaus set a $65.00 target price on AtriCure in a research report on Thursday, September 17th. Seven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $54.10.

Insider Buying and Selling at AtriCure

In other AtriCure news, insider Karl Dahlquist sold 9,370 shares of AtriCure stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the sale, the insider owned 87,319 shares of the company’s stock, valued at $4,269,025.91. The trade was a 9.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Salvatore Privitera sold 4,519 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $60.00, for a total transaction of $271,140.00. Following the transaction, the insider owned 142,745 shares in the company, valued at $8,564,700. The trade was a 3.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 74,868 shares of company stock valued at $3,317,897. 4.00% of the stock is currently owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.